new ORAL agent for rheumatoid arthritis, Xeljanz (ZEL-jans, tofacitinib)
January 2013
You'll hear about a new ORAL agent for rheumatoid arthritis, Xeljanz (ZEL-jans, tofacitinib).
Think of Xeljanz as an alternative to methotrexate for reducing joint inflammation.
Expect to see Xeljanz added on when methotrexate doesn't work...or used instead when methotrexate can't be taken due to side effects.
Practical advice for a better career, with unlimited access to CE
Pharmacy Technician's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 120+ CE courses, including the popular CE-in-the-Letter
- Helpful, in-depth Technician Tutorials
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote